Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Patel, Nimesh S A ^a   Nandra, Kiran K ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PLACEBO;

ACUTE KIDNEY FAILURE; BLEEDING; BRAIN ISCHEMIA; CARBAMOYLATION; DRUG EFFECT; DRUG EFFICACY; ERYTHROPOIESIS; HEART PROTECTION; HUMAN; INTENSIVE CARE; LOW DRUG DOSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; TISSUE INJURY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES;

CRITICAL CARE; ERYTHROPOIETIN; HUMANS;

EID: 84864350546     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11315     Document Type: Review

References (63)

1. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 2003, 42:142-149. 10.2169/internalmedicine.42.142, 12636232.
2. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998, 95:4635-4640. 10.1073/pnas.95.8.4635, 22542, 9539790.
3. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004, 22:63-69. 10.1097/01.shk.00001276869.21260.9d, 15201704.
4. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2003, 48:3544-3556. 10.1002/art.11351, 14674008.
5. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346. 10.1182/blood-2003-01-0223, 12702503.
6. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004, 66:983-989. 10.1111/j.1523-1755.2004.00847.x, 15327391.
7. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003, 198:971-975. 10.1084/jem.20021067, 2194205, 12975460.
8. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004, 19:348-355.
9. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505. 2040012, 12435860.
10. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C, EPO Stroke Trial Group Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-656. 10.1161/STROKEAHA.109.564872, 19834012, EPO Stroke Trial Group.
11. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976. 10.1056/NEJMoa071533, 17804841.
12. Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care 2011, 1:40. 10.1186/2110-5820-1-40, 3224459, 21943500.
13. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242. 10.1126/science.1098313, 15247477.
14. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-1030. 10.1038/ki.2010.25, 20164823.
15. Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma 2008, 65:285-297. discussion 297-289, 10.1097/TA.0b013e31817f2c6e, 18695463.
16. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 2001, 21:857-864.
17. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 1974, 249:4202-4206.
18. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989, 73:84-89.
19. Dong YJ, Kung C, Goldwasser E. Receptor binding of asialoerythropoietin. J Cell Biochem 1992, 48:269-276. 10.1002/jcb.240480307, 1400613.
20. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen L, Cerami-Hand C, Wuerth JP, Cerami A, Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003, 100:6741-6746. 10.1073/pnas.1031753100, 164517, 12746497.
21. Okada T, Sawada T, Kubota K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation 2007, 84:504-510. 10.1097/01.tp.0000277672.02783.33, 17713435.
22. Mori S, Sawada T, Okada T, Kubota K. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 2008, 143:556-565. 10.1016/j.surg.2007.12.013, 18374054.
23. Sato T, Tanno M, Miki T, Yano T, Shimamoto K, Miura T. Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO. Cardiovasc Drugs Ther 2010, 24:401-408. 10.1007/s10557-010-6265-5, 20953685.
24. Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purification 2000, 18:13-17. 10.1159/000014403, 10686438.
25. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993, 268:11208-11216.
26. Grodberg J, Davis KL, Sykowski AJ. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur J Biochem 1993, 218:597-601. 10.1111/j.1432-1033.1993.tb18413.x, 8269950.
27. Satake R, Kozutsumi H, Takeuchi M, Asano K. Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta 1990, 1038:125-129. 10.1016/0167-4838(90)90020-G, 2107876.
28. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005, 102:2046-2051. 10.1073/pnas.0409329102, 548534, 15671158.
29. Imamura R, Isaka Y, Ichimaru N, Takahara S, Okuyama A. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007, 353:786-792. 10.1016/j.bbrc.2006.12.099, 17196938.
30. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004, 101:14907-14912. 10.1073/pnas.0406491101, 522054, 15456912.
31. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 2001, 104:291-300. 10.1016/S0092-8674(01)00213-6, 11207369.
32. Stomski FC, Woodcock JM, Zacharakis B, Bagley CJ, Sun Q, Lopez AF. Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors. J Biol Chem 1998, 273:1192-1199. 10.1074/jbc.273.2.1192, 9422786.
33. Hanazono Y, Sasaki K, Nitta H, Yazaki Y, Hirai H. Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochem Biophys Res Commun 1995, 208:1060-1066. 10.1006/bbrc.1995.1442, 7535525.
34. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997, 90:1867-1873.
35. Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med 1998, 1:235-241.
36. Ebie AZ, Fleming KG. Dimerization of the erythropoietin receptor transmembrane domain in micelles. J Mol Biol 2007, 366:517-524. 10.1016/j.jmb.2006.11.035, 17173930.
37. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264:405-432. 10.1111/j.1365-2796.2008.02024.x, 19017170.
38. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med 2012, 18:486-496.
39. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007, 19:634-645. 10.1016/j.cellsig.2006.08.014, 17045782.
40. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516. 10.1038/26773, 9774108.
41. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008, 105:10925-10930. 10.1073/pnas.0805594105, 2504825, 18676614.
42. Patel NS, Nandra KK, Brines M, Collino M, Wong WS, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiemermann C. A non-erythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med 2011, 17:883-892. 3188881, 21607291.
43. Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011, 17:194-200. 3060982, 21170473.
44. Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci USA 2010, 107:14357-14362. 10.1073/pnas.1003019107, 2922582, 20660739.
45. Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology 2011, 115:1084-1092. 10.1097/ALN.0b013e31822fcefd, 21873879.
46. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83:59-67. 10.1016/0092-8674(95)90234-1, 7553874.
47. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA, REVEAL Investigators Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011, 305:1863-1872. 10.1001/jama.2011.592, 21558517, REVEAL Investigators.
48. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032. 10.1056/NEJMoa0907845, 19880844, TREAT Investigators.
49. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098. 10.1056/NEJMoa065485, 17108343.
50. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009, 30:253-260. 10.1159/000223229, 19494484.
51. Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009, 146:506-514. 10.1016/j.surg.2009.03.022, 19715808.
52. Xu K, George I, Klotz S, Hay I, Xydas S, Zhang G, Cerami A, Wang J. Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure. J Cardiovasc Pharmacol 2010, 56:506-512. 10.1097/FJC.0b013e3181f4f05a, 20881614.
53. Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A. Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 2008, 17:135-141. 10.3727/000000008783907044, 18468243.
54. Cassis P, Azzollini N, Solini S, Mister M, Aiello S, Cugini D, Scudeletti P, Gagliardini E, Abbate M, Gallon L, Remuzzi G, Noris M. Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. Transplantation 2011, 92:271-279. 10.1097/TP.0b013e3182241106, 21705971.
55. Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M, Leist M, Blomgren K. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004, 91:900-910. 10.1111/j.1471-4159.2004.02769.x, 15525344.
56. Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N, Yilmaz O, La Torre D, Buemi M, Iacopino DG, Coleman T, Cerami A, Brines M, Tomasello F. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006, 4:310-318. 10.3171/spi.2006.4.4.310, 16619678.
57. Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Beek J, Leist M, Brines M, Cerami A, Ghezzi P. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006, 12:153-160. 1626597, 17088947.
58. Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Nitta N, Haneda M, Koya D, Uzu T, Kashiwagi A. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol 2008, 19:321-328. 10.1681/ASN.2007040481, 2396737, 18184858.
59. Price CD, Yang Z, Karlnoski R, Kumar D, Chaparro R, Camporesi EM. Effect of continuous infusion of asialoerythropoietin on short-term changes in infarct volume, penumbra apoptosis and behaviour following middle cerebral artery occlusion in rats. Clin Exp Pharmacol Physiol 2010, 37:185-192. 10.1111/j.1440-1681.2009.05257.x, 19650797.
60. Nakazawa J, Isshiki K, Sugimoto T, Araki S, Kume S, Yokomaku Y, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T. Renoprotective effects of asialoerythropoietin in diabetic mice against ischaemia-reperfusion-induced acute kidney injury. Nephrology (Carlton) 2010, 15:93-101. 10.1111/j.1440-1797.2009.01170.x, 20377776.
61. Yamashita T, Nonoguchi N, Ikemoto T, Miyatake S, Kuroiwa T. Asialoerythropoietin attenuates neuronal cell death in the hippocampal CA1 region after transient forebrain ischemia in a gerbil model. Neurol Res 2010, 32:957-962. 10.1179/016164110X12700393823336, 20444326.
62. Ogino A, Takemura G, Kawasaki M, Tsujimoto A, Kanamori H, Li L, Goto K, Maruyama R, Kawamura I, Takeyama T, Kawaguchi T, Watanabe T, Moriguchi Y, Saito H, Fujiwara T, Fujiwara H, Minatoguchi S. Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol 2010, 56:1949-1958. 10.1016/j.jacc.2010.04.068, 21109120.
63. Sasaki N, Sekiguchi M, Kikuchi S, Konno S. Effects of asialo-erythropoietin on pain-related behavior and expression of phosphorylated-p38 map kinase and tumor necrosis factor-alpha induced by application of autologous nucleus pulposus on nerve root in rat. Spine (Phila Pa 1976) 2011, 36:E86-94. 10.1097/BRS.0b013e3181f137a8, 21228694.